Der Kaninchen Monoklonal anti-MAP2 Antikörper (Klon 32M37) (ABIN7879708) detektiert spezifisch MAP2 in WB, IHC, ICC und IF.
Dieser Antikörper reagiert spezifisch mit Proben aus Human, Maus und Ratte.
Optimal dilution of the Phospho-MAP2 (Ser136) antibody should be determined by the researcher.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Store the Phospho-MAP2 (Ser136) antibody at -20oC.
Target
MAP2
(Microtubule-Associated Protein 2 (MAP2))
Andere Bezeichnung
MAP2
Hintergrund
Phospho-MAP2 (Ser136) antibody detects microtubule-associated protein 2 (MAP2) when phosphorylated at serine 136. MAP2 is a neuronal cytoskeletal protein that stabilizes microtubules and contributes to dendritic architecture, synaptic plasticity, and neuronal signaling. Phosphorylation at Ser136, mediated by kinases such as PKA and CaMKII, modulates MAP2's ability to bind microtubules and regulate cytoskeletal dynamics.
Research using Phospho-MAP2 (Ser136) antibody has demonstrated its importance in neuronal development and function. Phosphorylation at Ser136 reduces MAP2's affinity for microtubules, promoting reorganization of dendritic structures. This regulation is critical during synaptogenesis, axon guidance, and activity-dependent plasticity. In models of learning and memory, changes in Ser136 phosphorylation correlate with synaptic remodeling and behavioral adaptation.
In neurodegenerative disease, dysregulated MAP2 phosphorylation contributes to cytoskeletal instability and neuronal dysfunction. Aberrant phosphorylation patterns are observed in Alzheimer's disease, Parkinson's disease, and traumatic brain injury, where MAP2 loss or mislocalization signals neuronal damage. Monitoring Ser136 phosphorylation provides insights into neuronal health and disease progression.
MAP2 phosphorylation also influences interactions with signaling molecules and cytoskeletal regulators. By modulating dendritic morphology, phospho-MAP2 contributes to long-term potentiation and depression, essential processes underlying cognition. Altered Ser136 phosphorylation has been linked to psychiatric conditions, including schizophrenia and depression, where synaptic dysfunction is a hallmark.
Antibodies against phospho-MAP2 (Ser136) are validated for immunohistochemistry, immunofluorescence, and western blot. These reagents selectively detect the phosphorylated form, distinguishing it from total MAP2. Clone-based antibodies ensure reproducibility and specificity in complex neuronal systems.
NSJ Bioreagents supplies this Phospho-MAP2 (Ser136) antibody for studies in neurodevelopment, synaptic plasticity, and neurodegenerative disease.